In contrast, the patient in case 2 had a family history significant for HUS, normal ADAMTS13 activity and stool infectious studies, a high titer of anti-CFH autoantibody, and slow but excellent response to eculizumab, all of which favor a diagnosis of aHUS, with likely COVID-19 trigger. The gene discussed is CFH; the disease is COVID-19.